Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation

Benjamin C Storey, Natalie Staplin, Richard Haynes, Christina Reith, Jonathan Emberson, William G Herrington, David C Wheeler, Robert Walker, Bengt Fellström, Christoph Wanner, Martin J Landray, Colin Baigent, SHARP Collaborative Group (Bo Feldt-Rasmussen, members), Bo Friis Feldt-Rasmussen (Medlem af forfattergruppering)

    31 Citationer (Scopus)

    Abstract

    Markers of inflammation, including plasma C-reactive protein (CRP), are associated with an increased risk of cardiovascular disease, and it has been suggested that this association is causal. However, the relationship between inflammation and cardiovascular disease has not been extensively studied in patients with chronic kidney disease. To evaluate this, we used data from the Study of Heart and Renal Protection (SHARP) to assess associations between circulating CRP and LDL cholesterol levels and the risk of vascular and non-vascular outcomes. Major vascular events were defined as nonfatal myocardial infarction, cardiac death, stroke or arterial revascularization, with an expanded outcome of vascular events of any type. Higher baseline CRP was associated with an increased risk of major vascular events (hazard ratio per 3x increase 1.28; 95% confidence interval 1.19-1.38). Higher baseline LDL cholesterol was also associated with an increased risk of major vascular events (hazard ratio per 0.6 mmol/L higher LDL cholesterol; 1.14, 1.06-1.22). Higher baseline CRP was associated with an increased risk of a range of non-vascular events (1.16, 1.12-1.21), but there was a weak inverse association between baseline LDL cholesterol and non-vascular events (0.96, 0.92-0.99). The efficacy of lowering LDL cholesterol with simvastatin/ezetimibe on major vascular events, in the randomized comparison, was similar irrespective of CRP concentration at baseline. Thus, decisions to offer statin-based therapy to patients with chronic kidney disease should continue to be guided by their absolute risk of atherosclerotic events. Estimation of such risk may include plasma biomarkers of inflammation, but there is no evidence that the relative beneficial effects of reducing LDL cholesterol depends on plasma CRP concentration.

    OriginalsprogEngelsk
    TidsskriftKidney International
    Vol/bind93
    Udgave nummer4
    Sider (fra-til)1000-1007
    ISSN0085-2538
    DOI
    StatusUdgivet - 2018

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation'. Sammen danner de et unikt fingeraftryk.

    Citationsformater